Carcinoma, Endometrioid: all 76 studies

Page 1 of 1. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.

• PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial CancerRecruitingNCT06549855Not applicable
• Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial CancerRecruitingNCT06468215Not applicable
• Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial CancerRecruitingNCT06463028Phase 2
• Fertility-sparing Therapy for Patients With Stage IA Endometrial CancerRecruitingNCT05945407Not applicable
• Medroxyprogesterone Acetate vs LNG-IUS in Early-stage Endometrioid Carcinoma and Atypical Hyperplasia PatientsRecruitingNCT05565573Phase 2/3
• AMT-151 in Patients With Selected Advanced Solid TumoursRecruitingNCT05498597Phase 1
• Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaRecruitingNCT05112601Phase 2
• Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian CancerRecruitingNCT05080556Phase 2
• Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their DiseaseRecruitingNCT04291612
• A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)TerminatedNCT03824704Phase 2Results posted
• Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneActive, not recruitingNCT03660826Phase 2Results posted
• The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer SurvivorsTerminatedNCT03641287Not applicableResults posted
• Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine CancersTerminatedNCT03345784Phase 1Results posted
• Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial CancerCompletedNCT03018249Early Phase 1Results posted
• Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT02923739Phase 2Results posted
• Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02853318Phase 2Results posted
• Copanlisib in Treating Patients With Persistent or Recurrent Endometrial CancerCompletedNCT02728258Phase 2Results posted
• Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02713386Phase 1/2Results posted
• Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial CancerCompletedNCT02684227Phase 2Results posted
• Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT02283658Phase 2Results posted
• Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial CancerCompletedNCT01935934Phase 2Results posted
• Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian CancerTerminatedNCT01275664Not applicableResults posted
• Trebananib in Treating Patients With Persistent or Recurrent Endometrial CancerCompletedNCT01210222Phase 2Results posted
• First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube CancerCompletedNCT01097746Phase 2Results posted
• Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerCompletedNCT01010126Phase 2Results posted
• Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or CisplatinCompletedNCT00993616Phase 2Results posted
• A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00939809Phase 2Results posted
• Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00888615Phase 2Results posted
• Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial CancerStatus unknownNCT00492778Phase 2Results posted
• Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial CancerCompletedNCT00478426Phase 2Results posted
• Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous ChemotherapyCompletedNCT00466960Phase 2Results posted
• Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00262847Phase 3Results posted
• Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube CancerStatus unknownNCT00108745Phase 3Results posted
• Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine CorpusCompletedNCT00064025Phase 2Results posted
• Erlotinib Plus Carboplatin and Paclitaxel in Ovarian CarcinomaCompletedNCT00059787Phase 2Results posted
• Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial CancerCompletedNCT00006011Phase 3Results posted
• Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian CancerWithdrawnNCT06393751Phase 1/2
• PET/MRI in Endometrial CancerWithdrawnNCT05390021Not applicable
• Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor TherapyWithdrawnNCT05295589Phase 2
• A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)TerminatedNCT05001282Phase 1/2
• [SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial CancerCompletedNCT04972682Not applicable
• A Study to Evaluate the Combination of ATX-101 and Platinum-based ChemotherapyTerminatedNCT04814875Phase 1/2
• Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic CancersWithdrawnNCT04611139Phase 1
• Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic CancerWithdrawnNCT04498520Phase 1
• Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.CompletedNCT04458597Not applicable
• ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no LossActive, not recruitingNCT04065269Phase 2
• Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube CancersTerminatedNCT03924245Phase 1
• Phase I Trial of Defactinib and VS-6766.Active, not recruitingNCT03875820Phase 1
• Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial CancersCompletedNCT03748186Phase 1
• Evaluation of the Efficacy for Sentinel Lymph Node Policy in Intermediate-risk Endometrial CarcinomasWithdrawnNCT03677024Not applicable
• Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)CompletedNCT03648489Phase 2
• Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 2
• Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.CompletedNCT02598219Phase 3
• The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting HysterectomyStatus unknownNCT02335203Phase 2
• POEM STUDY: A Phase IIa Trial in Endometrial Carcinoma With TemsirolimusCompletedNCT02093598Phase 2
• Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological CancersCompletedNCT02020707Phase 1
• Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC)WithdrawnNCT01732432
• Improving the Treatment for Women With Early Stage Cancer of the UterusActive, not recruitingNCT01686126Phase 2
• Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT01504126Early Phase 1
• Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing ChemotherapyWithdrawnNCT01492920Phase 3
• EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT01489371Phase 1
• Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT01459380Phase 1
• Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial CancerCompletedNCT01440998Phase 1
• TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity CancerCompletedNCT01294293Phase 1
• Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving ChemotherapyCompletedNCT01080521
• Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT01074411Phase 1
• Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00989651Phase 1
• YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving ChemotherapyTerminatedNCT00899093
• Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus unknownNCT00719303Phase 3
• Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube CancerCompletedNCT00357448Phase 1
• Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)CompletedNCT00085358Phase 1
• Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00079430Phase 1
• Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube CancerCompletedNCT00060359Phase 1
• Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic CancerCompletedNCT00028496Phase 1
• Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian CancerTerminatedNCT00004221Phase 2
• Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian CancerCompletedNCT00002913Phase 1

← Carcinoma, Endometrioid overview